美国 · SEC FORM 4
Nuo Therapeutics, Inc.
AURX · OTC · CIK 0001091596 · Healthcare · Biotechnology
内部人信号
1 位买方 · 2 条买入交易行 · $9.5K 买入总额
为什么有这个信号?
评分构成
每条进度条表示其对当前分数的贡献;权重和公式保持不变。
哪些因素限制了当前分数?
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ 角色得分低 · 买入者中职位最高的是:CEO/CFO(CEO、董事长和持股 10% 以上的股东得分最低)
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: CEO/CFO. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 36.2
- 36.1
- 36.0
- 35.9
- 35.8
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- +4.0%
- 3M
- +35.3%
- 6M
- -23.5%
- 12M
- -46.7%
波动率与流动性
- 波动率
- 96.2%
- Beta
- —
- 平均每日成交额
- USD 4,000
估值
- 市值
- USD 63.0M
- P/E
- —
基本面
- 利润率
- -75.8%
- ROE
- —
- 细分行业
- Biotechnology
市场数据
价格数据截至:2026-10-09 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, 利润率 · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-12 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 551
- 上期报告
- 5,153
- 日均成交量
- 4,968
- 回补天数
- ≤ 1.0
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | JORDEN DAVID EMERSON | 买入 (P) | Common Stock | 7,984 | USD 1.09 | USD 8,703 | SEC 申报 ↗ |
| 2026-08-27 | JORDEN DAVID EMERSON | 买入 (P) | Common Stock | 789 | USD 1.07 | USD 844 | SEC 申报 ↗ |
| 2025-07-30 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 133,333 | USD 1.50 | USD 200,000 | SEC 申报 ↗ |
| 2024-09-18 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 125,000 | USD 0.75 | USD 93,750 | SEC 申报 ↗ |
| 2024-05-20 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 100,000 | USD 0.75 | USD 75,000 | SEC 申报 ↗ |
| 2023-12-19 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 150,000 | USD 0.50 | USD 75,000 | SEC 申报 ↗ |
| 2023-08-01 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 62,500 | USD 2.00 | USD 125,000 | SEC 申报 ↗ |
| 2022-04-29 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 804,868 | USD 1.00 | USD 804,868 | SEC 申报 ↗ |
| 2020-10-05 | SHEEDY CHARLES E | 买入 (P) | Common Stock | 175,000 | USD 0.40 | USD 70,000 | SEC 申报 ↗ |
Form 4 申报证据
20 transaction lines in the latest 365-day window; 67 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | JORDEN DAVID EMERSON | 买入 (P) | Common Stock | 7,984 | USD 1.09 | USD 8,703 | SEC 申报 ↗ |
| 2026-08-28 | JORDEN DAVID EMERSON | 奖励/授予 (A) | Common Stock | 7,984 | USD 1.09 | USD 8,703 | SEC 申报 ↗ |
| 2026-08-27 | JORDEN DAVID EMERSON | 买入 (P) | Common Stock | 789 | USD 1.07 | USD 844 | SEC 申报 ↗ |
展开近期 Form 4 证据 (20 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | JORDEN DAVID EMERSON | 买入 (P) | Common Stock | 7,984 | USD 1.09 | USD 8,703 | SEC 申报 ↗ |
| 2026-08-28 | JORDEN DAVID EMERSON | 奖励/授予 (A) | Common Stock | 7,984 | USD 1.09 | USD 8,703 | SEC 申报 ↗ |
| 2026-08-27 | JORDEN DAVID EMERSON | 买入 (P) | Common Stock | 789 | USD 1.07 | USD 844 | SEC 申报 ↗ |
| 2026-08-27 | JORDEN DAVID EMERSON | 奖励/授予 (A) | Common Stock | 789 | USD 1.07 | USD 844 | SEC 申报 ↗ |
| 2026-06-30 | WINZER C ERIC | 期权行权/转换 (M) | Common Stock | 40,000 | USD 1.00 | USD 40,000 | SEC 申报 ↗ |
| 2026-06-30 | WINZER C ERIC | 代扣税 (F) | Common Stock | 39,604 | USD 1.01 | USD 40,000 | SEC 申报 ↗ |
| 2026-06-30 | Pittman Scott M. | 期权行权/转换 (M) | Common Stock | 40,000 | USD 1.00 | USD 40,000 | SEC 申报 ↗ |
| 2026-06-30 | Pittman Scott M. | 代扣税 (F) | Common Stock | 39,604 | USD 1.01 | USD 40,000 | SEC 申报 ↗ |
| 2026-06-30 | JORDEN DAVID EMERSON | 期权行权/转换 (M) | Common Stock | 162,500 | USD 1.00 | USD 162,500 | SEC 申报 ↗ |
| 2026-06-30 | JORDEN DAVID EMERSON | 代扣税 (F) | Common Stock | 160,892 | USD 1.01 | USD 162,501 | SEC 申报 ↗ |
| 2026-06-05 | JORDEN DAVID EMERSON | 奖励/授予 (A) | Common Stock | 13,245 | USD 1.10 | USD 14,570 | SEC 申报 ↗ |
| 2026-01-01 | JORDEN DAVID EMERSON | 期权行权/转换 (M) | Common Stock | 125,000 | USD 0.40 | USD 50,000 | SEC 申报 ↗ |
| 2026-01-01 | JORDEN DAVID EMERSON | 代扣税 (F) | Common Stock | 25,381 | USD 1.97 | USD 50,001 | SEC 申报 ↗ |
| 2025-12-17 | WINZER C ERIC | 期权行权/转换 (M) | Common Stock | 68,750 | USD 0.40 | USD 27,500 | SEC 申报 ↗ |
| 2025-12-17 | WINZER C ERIC | 代扣税 (F) | Common Stock | 13,750 | USD 2.00 | USD 27,500 | SEC 申报 ↗ |
| 2025-12-09 | Mintz Paul | 期权行权/转换 (M) | Common Stock | 50,000 | USD 0.40 | USD 20,000 | SEC 申报 ↗ |
| 2025-12-09 | Mintz Paul | 期权行权/转换 (M) | Common Stock | 50,000 | USD 0.40 | USD 20,000 | SEC 申报 ↗ |
| 2025-12-09 | Mintz Paul | 代扣税 (F) | Common Stock | 9,091 | USD 2.20 | USD 20,000 | SEC 申报 ↗ |
| 2025-12-09 | Mintz Paul | 代扣税 (F) | Common Stock | 9,091 | USD 2.20 | USD 20,000 | SEC 申报 ↗ |
| 2025-11-28 | JORDEN DAVID EMERSON | 卖出 (S) | Common Stock | 200,000 | USD 1.50 | USD 300,000 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AURX |
| CIK | 0001091596 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 3841 Surgical & Medical Instruments & Apparatus |
| 交易所 | OTC |
数据覆盖
| 本地 Form 4 历史 | 67 transaction lines from 2020-10-05 to 2026-08-28 9 P purchase lines · 8 S sale lines · 50 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.